Abstract
Primary sclerosing cholangitis (PSC) represents the greatest unmet need in modern hepatology, given its ill-defined aetiology, critical absence of medical therapy, and the fact that liver transplantation remains the only life-saving intervention for patients. Although rare, PSC now accounts for 10–15% of all liver transplant activity in European liver transplant programmes, and is now the lead indication for transplantation in Nordic countries.
However, rates of progression vary, and accurately predicting the disease course is of relevance to clinical practice and interventional trial design.
Patient expectations are also rising, with a feeling that doctors must be able to tell them if they are at risk, if so in what way, and with a reasonable degree of confidence.
However, rates of progression vary, and accurately predicting the disease course is of relevance to clinical practice and interventional trial design.
Patient expectations are also rising, with a feeling that doctors must be able to tell them if they are at risk, if so in what way, and with a reasonable degree of confidence.
Original language | English |
---|---|
Pages (from-to) | 867-870 |
Number of pages | 4 |
Journal | Journal of Hepatology |
Volume | 71 |
Issue number | 5 |
Early online date | 9 Sept 2019 |
DOIs | |
Publication status | Published - 1 Nov 2019 |
Bibliographical note
Article in press. Online version available 9 September 2019. https://doi.org/10.1016/j.jhep.2019.08.013Author ORCID Id: 0000-0002-4009-8087
Keywords
- Primary sclerosing cholangitis
- PSC
- Amsterdam Oxford PSC Score
- UK PSC Risk score
- prognostic model
- clinical trial
- biomarker